SymbolNDRA
NameENDRA LIFE SCIENCES INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
Address3600 GREEN COURT,SUITE 350, ANN ARBOR, Michigan, 48105, United States
Telephone+1 734 335-0468
Fax
Email
Websitehttps://www.endrainc.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001681682
Description

ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

Additional info from NASDAQ:
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

2026-06-29 22:30

New Form SCHEDULE 13D/A - ENDRA Life Sciences Inc. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001213900-26-073318 <b>Size:</b> 61 KB

Read more
2026-06-26 07:17

New Form 425 - ENDRA Life Sciences Inc. <b>Filed:</b> 2026-06-26 <b>AccNo:</b> 0001213900-26-072270 <b>Size:</b> 31 MB

Read more
2026-06-25 22:24

📋 Anthony DiGiandomenico (Board Member) plans to sell 71K shares of Endra Life Sciences Inc. (at $6.00 each, total $425K) Filed: Jun 25, 2026 | ID: 072178

Read more
2026-06-25 18:26

New Form 425 - ENDRA Life Sciences Inc. <b>Filed:</b> 2026-06-25 <b>AccNo:</b> 0001477932-26-004021 <b>Size:</b> 6 MB

Read more
2026-06-25 17:44

NDRA Stock Alert: Halper Sadeh LLC is Investigating Whether ENDRA Life Sciences Inc. is Obtaining a Fair Price for its Shareholders

Read more
2026-06-25 13:51

ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing

Read more
2026-06-25 13:37

(19% Negative) ENDRA LIFE SCIENCES INC. (NDRA) Announces Business Combination

Read more
2026-06-25 10:39

New Form 425 - ENDRA Life Sciences Inc. <b>Filed:</b> 2026-06-25 <b>AccNo:</b> 0001213900-26-071806 <b>Size:</b> 51 KB

Read more
2026-05-28 10:07

(99% Neutral) ENDRA LIFE SCIENCES INC. (NDRA) Announces Business Combination

Read more
2026-05-26 18:00

New Form RW - ENDRA Life Sciences Inc. <b>Filed:</b> 2026-05-26 <b>AccNo:</b> 0001213900-26-061074 <b>Size:</b> 8 KB

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT04302051 Assessment of Fatty Liver With Thermo-acoustic Device NASH Withdrawn 2023-11-02 2026-12-31 ClinicalTrials.gov
Total clinical trials: 1
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
MRI-PDFF estimation of hepatic fat Other Preclinical NASH WITHDRAWN NCT04302051
Thermo-acuostic image acquisition of liver Other Preclinical NASH WITHDRAWN NCT04302051
Total products: 2